• 139. Back to Basics - Early HER2 Breast Cancer

  • Dec 8 2024
  • Durata: 25 min
  • Podcast

139. Back to Basics - Early HER2 Breast Cancer

  • Riassunto

  • Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood.


    This week, we explore the original wonder drug (Trastuzumab) in the early breast cancer space and its compatriot, Pertuzumab. Josh highlights the association between pathological complete responses and event-free survival/overall survival, while Michael looks at Neosphere and picks apart the data to help understand where this drug is most beneficial.



    Studies discussed in the episode:

    NEOSPHERE

    GEPARQUINTO

    NOAH TRIAL


    For more episodes, resources and blog posts, visit www.inquisitiveonc.com

    Please find us on Twitter @InquisitiveOnc!

    If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


    Art courtesy of Taryn Silver

    Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


    Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


    Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


    Hosted on Acast. See acast.com/privacy for more information.

    Mostra di più Mostra meno

Cosa pensano gli ascoltatori di 139. Back to Basics - Early HER2 Breast Cancer

Valutazione media degli utenti. Nota: solo i clienti che hanno ascoltato il titolo possono lasciare una recensione

Recensioni - seleziona qui sotto per cambiare la provenienza delle recensioni.